ALUMIS INC. 8K

Alumis Inc. announced Q2 2026 results, showcased positive long-term envudeucitinib psoriasis data with an NDA planned for Q4 2026, detailed key upcoming lupus and TYK2 pipeline milestones, and recorded an impairment on its lonigutamab program while affirming cash runway into late 2027.

On August 13, 2026, Alumis Inc. reported its second quarter 2026 financial results and provided a comprehensive pipeline update, highlighting strong long-term Phase 3 ONWARD3 data for envudeucitinib in moderate-to-severe plaque psoriasis, its plan to submit a New Drug Application for envudeucitinib to the FDA in the fourth quarter of 2026, anticipated potentially pivotal Phase 2b LUMUS topline data in systemic lupus erythematosus in the third quarter of 2026, and its strategic prioritization of additional TYK2-driven indications and programs—including Sjögren’s disease, cutaneous lupus erythematosus and A-005 in Parkinson’s disease—while recording a $41.8 million impairment related to the lonigutamab program and projecting that its $502.3 million in cash, cash equivalents and marketable securities will fund operations into the fourth quarter of 2027.

Filing Facts

CIK

1847367

Ticker

ALMS

Form

8K

Source Type

fda

Accession

0001847367-26-000016

Alert Tier

6